Biospecimen procurement and tissue microarray manufacture for the CHTN

弗吉尼亚大学(UVA)目前支持合作人类组织的“成人”中大西洋分部 组织网络(CHTN)，提供高质量的人体组织和生物液样本，采购、存储和 根据优化的标准操作程序发货。一组同意工作人员在弗吉尼亚大学招募受试者 诊所，同意包括基因测序和数据共享以及捐赠的规定 组织、血液和骨髓样本。人员配备、程序和基础设施到位，以最大限度地减少 采购次数和组织样本由委员会认证的组织学检查进行质量控制 病理学家。获取的组织标本以新鲜冷冻、化学固定、石蜡- 嵌入的和可行的形式。我们计划继续这一活动，但要扩大我们目前的地理区域 并提供来自更多样化的捐赠者群体的生物标本。为此，我们与两家公司合作 其他招聘/采购网站，专门用于扩大样品采购，并提供 地理和种族/民族多样性。UVA将加入医学会采购生物素的行列 南卡罗来纳大学(MUSC)，这所大学的非裔美国人患者比例明显更高 新墨西哥大学(UNM)的拉美裔美国人比例要高得多 患者比UVA患者多。作为CHTN目前为数不多的能够获得新鲜和冷冻样品的部门之一 前列腺癌，我们建议继续为CHTN的研究人员提供这一宝贵的资源。我们也 建议继续专注于为CHTN构建组织微阵列(TMA)，以帮助补充 CHTN(预期可定制的纸巾采购)的传统优势 标本为TMA格式，具有更丰富的临床数据注释。我们提供带注释的数据的能力是 通过与弗吉尼亚大学的数字临床数据储存库和已建立的肿瘤登记处的集成而得到加强。 凭借在临床信息学方面的专业知识，我们建议通过以下方式增强当前的CHTN数据结构 映射到标准临床诊断数据模型(LOINC、SNOMED)并增强特定于生物存储库的功能 通过开发数据模型(BRISQ、SPREC、OBIB等)捕获数据。进一步加强生物检疫工作 向CHTN调查人员提供，我们有机会提供大量遗留的肺癌集合 来自肺癌生物样本资源网络的生物样本。我们建议扩大组织学指导- 宏观解剖服务，以创造增值的目标组织丰富和组织质量控制。我们会 还提供分离组织和分离的白细胞的可行冷冻，以及DNA/RNA分离 从组织样本中提取。

The University of Virginia (UVA) currently supports the “adult” Mid-Atlantic Division of the Cooperative Human Tissue Network (CHTN), offering high quality human tissue and biofluid specimens procured, stored and shipped under optimized standard operating procedures. A team of consent staff recruit subjects at UVA clinics, with the consent including provisions for genetic sequencing and data sharing as well as donating tissue, blood and bone marrow samples. Staffing, procedures & infrastructure are in place to minimize procurement times and tissue samples are quality controlled by histologic examination by Board-certified Pathologists. Procured tissue specimens are made available in fresh-frozen, chemically-fixed, paraffin- embedded and viable form. We propose to continue this activity, but to expand our current geographic area and to offer biospecimens from a more diverse population of donors. To do so, we have partnered with two other recruitment/procurement sites specifically to augment specimen procurement as well as provide geographic and racial/ethnic diversity. UVA will be joined in biospecimen procurement by the Medical University of South Carolina (MUSC), which has a significantly higher percentage of African-American patients than UVA, and by the University of New Mexico (UNM), which has a significantly higher percentage of Hispanic patients than UVA. As one of the few current CHTN divisions able to procure fresh and frozen samples of prostate cancer, we propose to continue to offer this precious resource to CHTN investigators. We also propose to continue our focus on constructing tissue microarrays (TMAs) for the CHTN, to help supplement the traditional strengths of the CHTN (prospective customizable procurement of tissue) with larger cohorts of specimens in TMA format, with more rich annotation of clinical data. Our ability to provide annotated data is enhanced by integration with a digital Clinical Data Repository at UVA and with an established tumor registry. With noted expertise in clinical informatics, we propose to enhance the current CHTN data structure with mapping to standard clinical diagnostic data models (LOINC, SNOMED) and to enhance biorepository-specific data capture with developing data models (BRISQ, SPREC, OBIB, etc.). To further augment biospecimens available to CHTN investigators, we have the opportunity to provide a large legacy collection of lung cancer biospecimens from the Lung Cancer Biospecimen Resource Network. We propose to expand histology guided- macrodissection services to create value-added target tissue enrichment and histologic quality control. We will also provide viable freezing of dissociated tissue and isolated white blood cells, as well as DNA/RNA isolation from tissue specimens.